Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 3 1

Status

Unknown 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Conditions

Heart Failure 2Cardiotoxicity 2Neoplasms 1Lymphoma 1

Interventions

Doxorubicin 15Exercise 9Cyclophosphamide 9Dexrazoxane 8Razoxane 6Carvedilol 6Vincristine 4Trastuzumab 4Radiotherapy 4Filgrastim 4Docetaxel 4Methotrexate 3Granulocyte Colony-Stimulating Factor 3Etoposide 3Echocardiography 3Atorvastatin 3salicylhydroxamic acid 2sacubitril and valsartan sodium hydrate drug combination 2empagliflozin 2dapagliflozin 2Tablets 2Silymarin 2Prednisone 2Paclitaxel 2Neoadjuvant Therapy 2Leucovorin 2Ivabradine 2High-Intensity Interval Training 2Epirubicin 2Electrocardiography 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Cardiotoxicity × Ivabradine × Clear all
NCT04030546 2019-12-18

Ivabradine to Prevent Anthracycline-induced Cardiotoxicity

Vilnius University

Phase 3 Unknown
128 enrolled

Heart Failure, Cardiotoxicity

NCT03650205 2019-04-02

IPAC

University of Sao Paulo

Phase NA Unknown
160 enrolled

Heart Failure, Neoplasms, Cardiotoxicity

Data powered by HemOnc (CC BY 4.0) Colophon âš¡